Healthy
Conditions
Keywords
ACT-451840, Safety, Tolerability, Pharmacokinetics
Brief summary
The primary objective of the study was to evaluate the safety and tolerability of ACT-451840 in healthy male subjects.Secondary objectives were : to investigate the pharmacokinetics (PK) of ACT-451840; to investigate the effect of food on the PK of ACT-451840; to evaluate the urinary excretion of ACT-451840 and to investigate the antimalarial activity of ACT-451840.
Interventions
DRUGACT-451840 10 mg
ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
DRUGACT-451840 50 mg
ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
DRUGACT-451840 200 mg
ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
DRUGACT-451840 500 mg
ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
DRUGACT-451840 1000 mg
ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
DRUGACT-451840 (Dose to be determined)
ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
DRUGPlacebo
Sponsors
Idorsia Pharmaceuticals Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Signed informed consent in the local language prior to any study-mandated procedure. * Body mass index (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at screening. * Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse rate 45-90 beats per minute (inclusive), measured on the dominant arm, after 5 min in the supine position at screening. * 12-lead electrocardiogram without clinically relevant abnormalities, measured after 5 min in the supine position at screening. * Hematology, coagulation, clinical chemistry, and urinalysis test results not deviating from the normal range to a clinically relevant extent at screening. * No clinically significant findings on the physical examination at screening. * Negative results from urine drug screen at screening. * Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study. * Subject covered by Health Insurance system and/or in compliance with the recommendations of the National Law in force relating to biomedical research. * If the subject's partner could become pregnant, reliable methods of contraception must be used from the time of the first administration of study medication until 3 months following administration of the last dose of study medication.
Exclusion criteria
* Known allergic reactions or hypersensitivity to any excipient of the drug formulation(s). * History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drug. * Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions. * Documented history of chronic liver or gall bladder disease. * Documented history of hemolytic anemia. * Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access, or puncture, veins with a tendency to rupture during or after puncture). * Previous exposure to the study medication. * Treatment with another investigational drug within 3 months prior to screening or participation in more than four investigational drug studies within the 12 months prior to screening. * Subject in the exclusion period of a previous clinical study. * Subject who had received more than 4,500 Euros as indemnities for his participation in a biomedical research within the 12 last months, including the indemnities for the present study. * History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening. * Excessive caffeine consumption, defined as 800 mg or more per day at screening. * Smoking within 3 months prior to screening and inability to refrain from smoking during the course of the study. * Previous treatment with any prescribed or over-the-counter medications (including herbal medicines such as St. John's Wort) within 2 weeks prior to first study drug administration. * Loss of 250 mL or more of blood within 3 months prior to screening. * Positive results from the hepatitis (hepatitis B and C) serology, except for vaccinated subjects. * Positive results from human immunodeficiency virus serology at screening. * Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol. * Legal incapacity or limited legal capacity at screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of treatment-emergent electrocardiogram abnormalities from baseline up to end of study | 4 days | Treatment-emergent electrocardiogram abnormalities will be identified using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing. |
| Change in diastolic blood pressure from baseline up to end of study | 4 days | Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the dominant/same arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period. |
| Change in pulse rate from baseline up to end of study | 4 days | Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the dominant/same arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period. |
| Change in body weight from baseline up to end of study | 4 days | Body weight will be measured using the same weighing scale for all subjects and throughout the study. The weighing scale should have a precision of at least 0.5 kg. |
| Change in heart rate from baseline up to end of study | 4 days | Heart rate will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing. |
| Change in PQ/PR interval from baseline up to end of study | 4 days | PQ/PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex) will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing. |
| Change in QRS interval from baseline up to end of study | 4 days | QRS interval (time interval from the beginning of the Q wave to the end of the S wave) will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing. |
| Change in QTc interval (time interval from beginning of the Q wave until end of the T wave) according to Fridericia's correction (QTcF interval) from baseline up to end of study | 4 days | QTcF interval will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing. The QTcF interval is the QTc interval corrected for heart rate with Fridericia's formula (QTcB = QT/RR\^0.33 where RR is 60/heart rate) |
| Change in QTc interval (time interval from beginning of the Q wave until end of the T wave) according to Bazett's correction (QTcB interval) from baseline up to end of study | 4 days | QTcB interval will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing. The QTcB interval is the QTc interval corrected for heart rate with Bazett's formula (QTcB = QT/RR\^0.5 where RR is 60/heart rate). |
| Change in systolic blood pressure from baseline up to end of study | 4 days | Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the dominant/same arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to maximum plasma concentration (tmax) of ACT-451840 | 4 days | Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing. tmax will be calculated on the basis of the blood sampling time points. |
| Area under the plasma concentration-time curve (AUC(0-t)) of ACT-451840 | 4 days | Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing. AUC(0-t) will be calculated as the area under the plasma concentration-time profile from time zero to time t of the last measured concentration above the limit of quantification. |
| Area under the plasma concentration-time curve (AUC(0-infinity)) of ACT-451840 | 4 days | Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing. AUC(0-infinity) will be calculated by combining AUC(0-t) and AUC(extra). AUC(extra) represents an extrapolated value obtained by Ct/λz, where Ct is the last plasma concentration measured above the limit of quantification and λz represents the terminal elimination rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal elimination phase. |
| Plasma half life (t1/2) of ACT-451840 | 4 days | Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing. t1/2 will be calculated on the basis of the blood sampling time points. |
| Dose proportionality of single doses of ACT-451840 | 4 days | Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing. Dose proportionality will be explored by the power model as described by Gough et al \[1995\]. The power model will be applied to the loge AUC0-∞ and Cmax data. A point estimate and 90% Confidence Interval (CI) will be produced for the population mean slope. Approximate dose proportionality will be concluded if the 90% CI for the slope is completely contained in the range (1+log(0.5))/log(r), 1+log(2)/log(r) where r = high dose/low dose. |
| Percentage of administered ACT-451840 excreted unchanged in urine | 4 days | A baseline urine sample will be collected from each subject in the selected dose group after admission on Day -1. On Day 1, subjects will be instructed to empty their bladder immediately prior to study drug intake. Thereafter, all urine produced will be collected during the 4 days following study drug intake until the morning of Day 5. On Day 1, urine will be collected at three consecutive 8-hour intervals, from 0-8 hours, 8-16 hours, and 16-24 hours. On Days 2, 3, and 4 urine will be collected in 24-hours intervals. |
| Anti-malarial half-maximal inhibitory concentration (IC50) of ACT-451840 | 4 days | Blood (2.5 mL) will be collected by direct venipuncture or via an intravenous catheter placed in an antecubital vein in the arm into 3.5 mL vacutainer serum separation tubes. The anti-malarial IC50 of ACT-451840 will be determined using a bioassay and ACT-451840 IC50 concentrations will be estimated based on the measured antimalarial activity. |
| Maximum plasma concentration (Cmax) of ACT-451840 | 4 days | Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing. Cmax will be calculated on the basis of the blood sampling time points. |
Countries
France
Outcome results
None listed